metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	durvalumab plus tremelimumab
	DANUBE (DT vs C - all population), 2020 Urologe A 2016; 55:1097-8 Lancet Oncol 2020 Sep 21;S1470-2045(20)30541-6. NCT02516241	RCT	mUC - L1 - all population	durvalumab plus tremelimumab	platine based chemotherpy	first line in Patients with Stage IV Urothelial Cancer.	342 / 344	some concern	inconclusive
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
versus gemcitabine plus platin
	durvalumab plus tremelimumab
	DANUBE (DT vs C - PDL1>25%), 2020 Urologe A 2016; 55:1097-8 Lancet Oncol 2020 Sep 21;S1470-2045(20)30541-6. NCT02516241	RCT	mUC - L1 - PDL1 positive	durvalumab plus tremelimumab	platine based chemotherpy (SOC)	first line in Patients with Stage IV Urothelial Cancer with PDL1 high expression level	205 / 207	some concern	suggested